Multiple Myeloma

Experts gathered to discuss various facets of early-relapse multiple myeloma treatment, such as exposure vs refractoriness and CAR T vs bispecifics.

Data from the phase 3 EXCALIBER-RRMM trial support the FDA accelerated approval of iberdomide plus daratumumab and hyaluronidase and dexamethasone in this multiple myeloma population.

Ajay K. Nooka, MD, MPH, FACP, discusses how results from the MonumenTAL-6 trial build upon prior studies assessing bispecific antibodies in multiple myeloma.

Phase 1 trial data for cevostamab in multiple myeloma validate fixed-duration therapy as a “good concept,” according to Adam D. Cohen, MD.

Data from a phase 1 trial validate FcRH5 as a “good target” in multiple myeloma therapy, according to Adam D. Cohen, MD.

Data from the phase 3 MonumenTAL-6 trial demonstrate the potential to target BCMA and GPRC5D simultaneously in multiple myeloma care.

Patients with a multiple myeloma relapse within 36 months of up-front quadruplet therapy and transplantation should be prioritized for immunotherapy, said Gayathri Ravi, MD.

Data from the phase 3 ENDURANCE trial challenge the assumption that a longer duration of therapy is likely to better multiple myeloma care.

The FDA has assigned a Prescription Drug User Fee Act date of May 13, 2027, for the mezigdomide regimen in relapsed/refractory multiple myeloma.

Data from studies including the IRAKLIA trial support the approval of subcutaneous isatuximab plus standard of care in multiple myeloma.

Paul G. Richardson, MD; and Muhamed Baljevic, MD, FACP, discussed the mechanism, synergy, tolerability, and sequencing of CELMoDs in multiple myeloma.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss using CELMoDs to debulk tumor or restore T-cell fitness between T-cell–redirecting therapies in relapsed/refractory multiple myeloma.

Muhamed Baljevic, MD, FACP, and Paul Richardson, MD, discuss how sparing patients from IMiD-related GI toxicity and neutropenic infections with CELMoDs may extend treatment duration and progression-free survival.

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, discuss the immunologic and mechanistic synergy between CELMoDs and standard myeloma backbone therapies.

Paul Richardson, MD, and Muhamed Baljevic, MD, FACP, explain how mezigdomide’s complete cereblon E3 ligase engagement overcomes IMiD resistance in heavily pretreated multiple myeloma.

In this retrospective cohort study, it was shown that acute pancreatitis hospitalizations occurred more frequently in patients with multiple myeloma who were older and more medically complex.

Teclistamab-based induction yielded a 100% overall response rate in transplant-eligible newly diagnosed multiple myeloma in the phase 2 MajesTEC-5 trial.

The CHMP’s recommendation for approving teclistamab plus daratumumab in this multiple myeloma population is based on data from the phase 3 MajesTEC-3 study.

Joshua Richter, MD, joins The Moonlight Shift to discuss "cure" in relation to myeloma treatment, the linvoseltamab pipeline journey, and myths surrounding myeloma care.

The 2025 ICE-T Symposium highlighted expansion beyond BCMA to additional targets such as GPRC5D and FcRH5.

This year’s EHA Congress saw potential advances across multiple myeloma, leukemia, lymphoma, and other hematologic malignancy populations.

Data from a phase 1/2 trial show durable disease control with belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.

Phase 1 data support arlo-cel as a potentially effective early-line treatment option for those with relapsed/refractory multiple myeloma.

In MonumenTAL-3, talquetamab plus daratumumab with or without pomalidomide significantly improved PFS vs DPd in relapsed/refractory myeloma.

High rates of MRD negativity were observed with a combination of carfilzomib, lenalidomide, daratumumab, and dexamethasone in the ASCENT trial.